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Abstract
Sclerostin is a product of mature osteocytes embedded in mineralised bone and is a negative regulator of bone mass and
osteoblast differentiation. While evidence suggests that sclerostin has an anti-anabolic role, the possibility also exists that
sclerostin has catabolic activity. To test this we treated human primary pre-osteocyte cultures, cells we have found are
exquisitely sensitive to sclerostin, or mouse osteocyte-like MLO-Y4 cells, with recombinant human sclerostin (rhSCL) and
measured effects on pro-catabolic gene expression. Sclerostin dose-dependently up-regulated the expression of receptor
activator of nuclear factor kappa B (RANKL) mRNA and down-regulated that of osteoprotegerin (OPG) mRNA, causing an
increase in the RANKL:OPG mRNA ratio. To examine the effects of rhSCL on resulting osteoclastic activity, MLO-Y4 cells
plated onto a bone-like substrate were primed with rhSCL for 3 days and then either mouse splenocytes or human
peripheral blood mononuclear cells (PBMC) were added. This resulted in cultures with elevated osteoclastic resorption
(approximately 7-fold) compared to untreated co-cultures. The increased resorption was abolished by co-addition of
recombinant OPG. In co-cultures of MLO-Y4 cells with PBMC, SCL also increased the number and size of the TRAP-positive
multinucleated cells formed. Importantly, rhSCL had no effect on TRAP-positive cell formation from monocultures of either
splenocytes or PBMC. Further, rhSCL did not induce apoptosis of MLO-Y4 cells, as determined by caspase activity assays,
demonstrating that the osteoclastic response was not driven by dying osteocytes. Together, these results suggest that
sclerostin may have a catabolic action through promotion of osteoclast formation and activity by osteocytes, in a RANKL-
dependent manner.
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Introduction
Sclerostin (SCL) is the product of the SOST gene, mutations in
which cause the high bone mass disease in humans, sclerosteosis
[1]. Deletion of SOST in mice causes a similar high bone mass
phenotype [2]. Partial deletion of a regulatory region approxi-
mately 35 kb distal to the SOST gene is causative of the high bone
mass phenotype seen in Van Buchem’s disease [3,4,5]. These
findings together indicate that SCL has a key role in the regulation
of bone mass. SCL has been identified as a target for osteoporosis
treatment, with neutralizing antibody and small molecule inhibitor
approaches being pursued [6]. The signalling pathways, through
which SCL acts, are incompletely understood [7,8,9,10,11],
although it has inhibitory actions on bone morphogenetic protein
(BMP) signalling [8,12] and blocks canonical wingless integration
(Wnt) signalling by binding to the Wnt co-receptors, low density
lipoprotein receptor (LRP)-5 and 6 [13,14]. More recently, LRP4
has also been implicated as a major receptor for SCL [15,16]. We
reported recently that SCL stimulated a p42/p44 mitogen
activated protein kinase (MAPK) response in human primary
osteoblasts, suggesting the existence of additional pathways of
sclerostin activity than those described [17].
While attention has been generally focused on the anti-anabolic
actions of SCL, existing evidence suggests actions also on bone
resorption. Analysis of ovariectomized (OVX) rats treated with
neutralizing antibody to SCL showed protection against bone loss
and this was associated with a marked decrease in the histomor-
phometric parameter osteoclast surface, below the level seen in
shamOVX animals [18]. A study in 10 month-old intact female rats
revealed a bone formation effect of anti-SCL treatment and this was
associated with a dramatic inhibition of osteoclastic activity (eroded
surface) in these animals [19], consistent with an effect of sclerostin
on the osteoclast compartment. Furthermore, a recent report of a
phase I clinical trial in healthy human subjects showed that a single
subcutaneous or intravenous dose of a neutralizing antibody to
sclerostin resulted in a rapid and significant reduction of the serum
resorption marker, serum C-telopeptide of collagen (sCTx) [6].
These findings are consistent with the activity of sclerostin as a Wnt
inhibitor, since osteoprotegerin (OPG), a potent inhibitor of the pro-
osteoclastogenic RANKL-RANK signalling pathway, is expressed
in response to canonical [20] and potentially non-canonical [21]
Wnt signalling.
Sclerostin is expressed primarily by osteocytes in vivo [22,23].
Parathyroid hormone (PTH) treatment [24,25] and mechanical
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loading [26] likely exert an anabolic effect, at least in part, by
suppressing SCL expression. In contrast, catabolic stimuli appear
to increase SCL expression in bone, for example mechanical
unloading [23] or exposure of osteoblast-lineage cells to pro-
inflammatory cytokines such as tumour necrosis factor-alpha
(TNFa) and TNF-related weak inducer of apoptosis (TWEAK)
[17,27]. Osteocytes can express RANKL in vivo [28,29,30].
Furthermore the osteocyte cell line, MLO-Y4, can express
RANKL and support osteoclastogenesis [31,32]. We have
established a model of human osteocytes, with many of the
molecular and phenotypic characteristics of osteocytes, by
allowing normal human bone derived osteoblastic cells (NHBC)
to differentiate in long-term (4 to 5 weeks) culture [33,34,35]. We
have also recently identified the osteoblast to osteocyte transition
as an important physiological target for SCL [36].
In this study, we examined the effects of SCL on the expression
by pre-osteocytes/osteocytes of osteoclastogenesis associated
genes. We found that SCL confers a pro-osteoclastogenic
phenotype on both human primary pre-osteocytes and the mouse
osteocyte-like cell line, MLO-Y4 [37]. We report that SCL
stimulates osteocyte support of osteoclastogenesis and does so in a
RANKL-dependent manner. We conclude that SCL may have a
catabolic action in bone and that this in part explains the dramatic




The use of all normal human donor derived material was
approved by the human ethics committees of the Royal Adelaide
Hospital/University of Adelaide and the Red Cross Society of
Australia (Approval No.’s RAH090101 & 10-04SA-10). All human
material was obtained with informed written donor consent, as
required and approved by the respective ethics committees. The
use of animals in this study was approved by the animal ethics
committees of the Institute of Medical and Veterinary Science and
of the University of Adelaide (Approval No.’s 159/08 & ST05/
10). Animals were maintained and treated in accordance within
the strict ethical guidelines of these committees.
Recombinant cytokines and antibodies
Recombinant human (rh) sclerostin (rhSCL) and OPG (rhOPG)
were purchased from R&D Systems (Minneapolis, MN, USA).
Recombinant human RANKL and M-CSF were purchased from
Chemicon (Temecula, WA, USA).
Cells and culture media
Adult human primary osteoblasts (normal human bone-derived
cells; NHBC [38]) were isolated from femoral neck trabecular
bone and passaged, as we have described previously [39]. MLO-
Y4 cells were passaged solely on type I collagen-coated plates, as
described previously [37]. Mouse splenocytes were isolated and
prepared as described previously [40]. Human peripheral blood
mononuclear cells (PBMC) were obtained from normal buffy coats
and isolated using LymphoprepTM (Nycomed Pharma, Oslo,
Norway), as described previously [41].
In situ Immunofluorescence
NHBC were seeded into chamber slides (Lab-Tek, Nunc,
Naperville, IL, USA) and cultured for the times and under the
conditions indicated. Cells were then rinsed with PBS, fixed
with 4% paraformaldehyde in PBS for 10 min on ice, rinsed
with PBS and permeabilised with 0.1% Triton X100 for 5 min.
Non-specific binding sites were blocked with PBS containing
10% goat serum for 30 min at room temperature. The cells
were incubated for 30 min with primary antibodies. Following 3
washes in PBS, cells were incubated with either anti-mouse IgG-
FITC or anti-rabbit IgG-FITC for 45 min in a dark humidified
container. Cells were then washed in PBS and mounted
(Prolong Gold with DAPI anti-fade mounting media; Invitro-
gen). Samples were examined by confocal microscopy on a
Radiance 2100 confocal microscope (Bio-Rad Microscience
Ltd, UK).
Preparation of total RNA and RT-PCR
Total RNA was extracted from NHBC and cell lines treated as
above, and complementary DNA (cDNA) was prepared, and gene
expression analyzed by real-time RT-PCR as we have described
previously [42]. Relative expression between samples was
calculated using the comparative cycle threshold (CT) method
(DCT), using either 18S rRNA or GAPDH as reference genes, as
indicated and as we have published [40,42]. Oligonucleotide
primers were designed in-house to flank intron-exon boundaries,
and were purchased from Geneworks (Thebarton, SA, Australia).
Real-time oligonucleotide primers for the amplification of human
GAPDH, DMP1, SOST RANKL, OPG, 18S and mouse
RANKL mRNA species were described previously [34,42].
Sequences used for real-time RT-PCR amplification of mouse
OPG mRNA (122 bp product) were AGCTGGAACCCCA-
GAGCGAA (sense) and GCAGGAGGCCAAATGTGCTG (an-
tisense).
Gene expression experiments
To determine the ability of NHBC to form a mineralised
matrix, a modification of a method reported previously [43] was
used. Cells were cultured in triplicate in wells of a 96 well plate at
86103 cells/well for NHBC or 56103 cells/well for cell lines, in
aMEM-10 containing dexamethasone (1028 M) and KH2PO4
(1.8 mM) in the presence or absence of rhSCL. Mature, late
osteoblast/osteocyte-like cultures of NHBC were generated by
culturing for 35 days in mineralisation medium, as previously
described [36]. Cells were then treated with rhSCL (1, 10 or
50 ng/ml) for 3 or 7 days, and RNA prepared as described above.
Media containing all supplements were replaced every 4 days and
cells were cultured for up to 6 weeks before measurement of cell
layer-associated Ca2+ levels, as described previously [43].
Osteoclastogenesis Assays
MLO-Y4 cells were seeded at a density of 2.16104 cells/cm2
into type I collagen-coated wells of a 96-well plate for the
purposes of histological staining for tartrate resistant acid
phosphatase (TRAP). Alternatively, cells were seeded at an
identical density onto slices of whale dentine or into wells of
OsteologicTM slides for the purpose of quantification of resorptive
activity [40,41]. Following overnight incubation in seeding
medium, media were replaced with those containing varying
concentrations of rhSCL. After 3 days of priming under these
conditions, splenocytes or PBMC were added (5.36105 cells/cm2)
in medium containing the respective priming medium with
additional rhM-CSF (25 ng/ml). Control cultures included
monocultures of MLO-Y4 cells, splenocytes or PBMC, plated
with M-CSF and the same dose range of rhSCL used for co-
cultures, and also monocultures of splenocytes and PBMC plated
in the additional presence of rhRANKL (100 ng/ml). Media
were replaced every 3 days thereafter. Osteoclast number was
assessed by TRAP staining after 6–9 days, as described previously
[40]. Resorption was assessed 14 days following the addition of
Sclerostin Induces Osteoclastogenesis
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osteoclast precursors by von Kossa staining of the mineralised
surface and quantification using ImageJ software, as described
previously [40].
Caspase activity assays
MLO-Y4 cells were seeded into collagen-coated wells at an
identical density, 2.16104 cells/cm2, to that used for osteoclast-
forming co-cultures, as described above. Cells were treated with
rhSCL or etoposide (Pharmacia & Upjohn, Kalamazoo, MI, USA)
at the indicated doses and duration. Caspase activity was assayed
by cleavage of zDEVD-AFC (z-asp-glu-val-asp-7-amino-4-tri-
fluoro-methyl-coumarin), a fluorogenic substrate based on the
peptide sequence at the caspase-3 cleavage site of poly (ADP-
ribose) polymerase [44], essentially as described previously [45].
Briefly, following treatment, media were removed and non-
attached cells and cell debris were pelleted by centrifugation at
4006g for 10 min. This pellet and the cells remaining in the
respective wells were solubilised in buffer consisting of Tris-HCl
(5 mM, pH 7.5), EDTA (5 mM) and NP40 (0.5% v/v), for 15 min
at 4uC. Aliquots (20 ml) of cell lysates were added to fresh tubes
containing 1 ml of protease buffer (50 mM HEPES, 10% sucrose,
10 mM DTT, 0.1% CHAPS, pH 7.4) and zDEVD-AFC (8 mM,
Kamiya Biomedical Company, Seattle, WA, USA). Following
incubation for 4 h at room temperature, the resulting fluorescence
was measured (LS 50 Spectrofluorimeter, Perkin Elmer, San Jose,
CA, USA).
Assessment of nuclear morphology
MLO-Y4 cells were seeded on plastic chamber slides (Nunc) at
the same density as for co-culture experiments, as described above,
and stimulated as indicated. After two washes with PBS, cells were
fixed in methanol for 5 min, washed again with PBS, and
incubated with 0.8 mg/ml of 49,6-diamidine-29-phenylindole
dihydrochloride (DAPI, Roche Diagnostics, Castle Hill, NSW,
Australia) in PBS for 15 min at 37uC. After several washes in PBS,
the coverslips were mounted on PBS/glycerin. DAPI staining was
visualised by confocal microscopy, as above.
Statistical Analysis
Student’s t-Test was used to analyse differences in mineralisa-
tion and cell proliferation experiments. One way analysis of
variance (ANOVA) followed by Tukey’s post-hoc analysis was
used to examine differences in gene expression studies. A value for
p,0.05 was considered to be significant.
Results
Effect of exogenous sclerostin on gene expression during
osteoblast differentiation
To determine the effect of continuous exposure to exogenous
SCL on gene expression in human osteoblasts, we performed real-
time RT-PCR analysis of NHBC treated throughout differentia-
tion, for a period of up to 35 days, under conditions otherwise
permissive for mineralisation. Consistent with our previous studies
[33,35,36], this analysis showed that osteoblasts acquired the
expected gene profile consistent with differentiation into mature
cells with an osteocyte-like phenotype, including time-dependent
increases in mRNA levels of the markers DMP1 and SOST
(Fig. 1A and B), as well as osteocalcin, BSP-1 and PHEX (data not
shown). Continuous treatment with rhSCL (50 ng/ml) affected
gene expression primarily at the time of mineralisation, consistent
with late stage osteoblasts/early osteocytes being targets for SCL
action, and in agreement with our previous report [36]. In these
cultures, rhSCL strongly inhibited late expression of DMP1 and
SOST. rhSCL had little effect on OPG mRNA expression in
continuously treated cultures (Fig. 1C). However, rhSCL strikingly
up-regulated RANKL mRNA expression in long-term cultures
(Fig. 1D).
Because late-stage cultures exhibited greater sensitivity to
sclerostin in terms of osteoclastogenesis-associated gene expres-
sion and because we have identified late osteoblasts/pre-
osteocytes as SCL targets [36], we next cultured cells under
differentiating conditions for 35 days and then treated these
acutely with rhSCL. rhSCL dose-dependently increased RANKL
mRNA expression after 3 days (mean fold-change with rhSCL at
50 ng/ml of 9.764.7, n=3) with levels returning thereafter to
those of control cultures in all cases, while the lowest dose of
rhSCL used (1 ng/ml) had no effect (Fig. 2A). SCL treatment of
these late stage cultures caused a small change in OPG mRNA
expression, in the inverse direction to that of RANKL mRNA
(mean fold-change with rhSCL at 50 ng/ml of 21.360.2, n=3).
The decrease in OPG mRNA at 3 days and increase at 7 days of
treatment, resulted in a striking transient increase in the
RANKL:OPG mRNA ratio in primary cultures (Fig. 2B and
2C). SCL at 50 ng/ml also increased RANKL mRNA expression
in osteocyte-like MLO-Y4 cells, from an already relatively high
basal level (Fig. 2D). OPG mRNA levels were decreased in
MLO-Y4 cells, resulting in a sustained increase in the
RANKL:OPG mRNA ratio in these cells (Fig. 2E and 2F).
Together, these findings implied that SCL can promote a pro-
osteoclastic phenotype in osteocyte-like cells.
Figure 1. Effects on gene expression of continuous exposure of
mineralizing NHBC cultures to rhSCL. NHBC were cultured under
mineralizing conditions for up to 35 days in the absence or presence of
rhSCL at 50 ng/ml. Media were replenished every 3–4 days. At the time
points indicated, total RNA was prepared and real-time RT-PCR
performed to determine mRNA expression of A) DMP1, B) SOST, C)
OPG and D) RANKL. Data shown are means of triplicate reactions 6 SD
normalized to expression of 18S mRNA. Significant differences to
untreated control are indicated by * p,0.05 and *** p,0.001. Similar
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Effect of sclerostin on MLO-Y4 support of
osteoclastogenesis
Because MLO-Y4 cells express RANKL mRNA at higher
levels than NHBC in general, and because they represent a more
homogenous cell population, these cells were chosen to test the
possibility that SCL treatment could influence their support of
osteoclastogenesis. To do so, MLO-Y4 cells were first primed for
72 hours with rhSCL, using a similar dose range that affected
RANKL and OPG mRNA expression. Mouse splenocytes or
human PBMC were then added to the MLO-Y4 cells and the co-
cultures were continued for a further 5–7 days in the additional
presence of M-CSF. After this time, cultures were fixed and
stained for TRAP activity. Abundant TRAP+ cells formed in co-
cultures of MLO-Y4 cells with splenocytes, consistent with the
relatively high basal expression of RANKL by MLO-Y4 cells,
and rhSCL had little effect on the number of TRAP+ cells in
these cultures (Fig. 3A). SCL moderately increased TRAP+ cell
number in co-cultures with PBMC (Fig. 3B). In both cases,
TRAP+ cell formation was strongly inhibited with the addition of
OPG, in the presence or absence of rhSCL, showing that
osteoclast formation remained RANKL-dependent (Fig. 3). The
size of the TRAP+ multinucleate cells formed however was larger
in the added presence of rhSCL at the highest dose tested
(100 ng/ml, Fig. 3C). SCL had no effect on osteoclastogenesis in
Figure 2. Effects on gene expression of acute exposure of osteocyte-like cells to rhSCL. Human osteocyte-like cultures, derived from
NHBC cultured under mineralizing conditions for 35 days, or cultures of MLO-Y4 cells were cultured for 3 or 7 days in the absence of presence of
rhSCL at 1, 10 or 50 ng/ml. Media and supplements were replenished at day 3. Total RNA was prepared and real-time RT-PCR performed to determine
mRNA expression of A) human RANKL, B) human OPG or mouse Rankl (D) and Opg (E). The ratios of RANKL:OPG mRNA for NHBC (C) and MLO-Y4 (D)
were also determined. Data shown are means of triplicate reactions 6 SD normalized to expression of GAPDH mRNA. a, b and c indicate significant
differences (p,0.05) to untreated control for rhSCL at 1, 10 and 50 ng/ml, respectively. Near identical results were obtained from 3 independent
experiments using NHBC from different donors or MLO-Y4 cells.
doi:10.1371/journal.pone.0025900.g002
Sclerostin Induces Osteoclastogenesis
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monocultures of either splenocytes or PBMC treated with M-CSF
(not shown).
Effect of sclerostin on MLO-Y4 support of osteoclast
activity
To test the effect of SCL on osteoclast resorption, MLO-Y4 cells
were plated onto a mineralised collagen substrate and then treated
with rhSCL for 72 hours prior to the addition of either splenocytes
or PBMC. Cultures were continued in the additional presence of
M-CSF. rhSCL dose-dependently increased the extent of
osteoclastic resorption observed after 14 days (significant at
50 ng/ml), in both cases to a maximum of approximately 7-fold
at 100 ng/ml rhSCL (Fig. 4A–B). This was accompanied by an
increase in mean resorption pit size of 2–2.6-fold, consistent with
increased activity of the individual osteoclasts formed in the
presence of rhSCL at 50 and 100 ng/ml (Fig. 4C). The increase in
osteoclast activity in response to rhSCL was completely inhibited
by the co-addition of OPG, indicating that SCL was acting
through a RANKL-dependent pathway. In some experiments,
conditioned media were taken from MLO-Y4 cells treated with or
without rhSCL and tested for their ability to promote osteoclas-
togenesis; no effect was observed (data not shown), consistent with
the requirement for cell-cell contact for the rhSCL effect in this
model.[32] Importantly, no direct effects of rhSCL were observed
with respect to either TRAP+ cell formation or resorption in
monocultures of MLO-Y4 cells, splenocytes or PBMC cultured
only in the presence of M-CSF (data not shown).
Effect of rhSCL on MLO-Y4 apoptosis
Since osteocyte apoptosis has been shown to be a trigger for
recruitment and support by osteocytes of osteoclastogenesis, we
next investigated the effect of rhSCL on MLO-Y4 cell viability.
The effect of rhSCL in this regard was tested against the cytotoxic
drug, etoposide at a concentration (50 mM) we shown previously to
induce apoptosis in osteoblastic cell lines [45]. Treatment of
MLO-Y4 with doses of rhSCL up to100 ng/ml for up to 72 h had
no discernible effect on MLO-Y4 viability, as determined by their
nuclear morphology (Fig. 5A–D) and by caspase-3 activation
assays (Fig. 5E). This implies that SCL is capable of stimulating
osteoclastogenesis and osteoclast activity independently of osteo-
cyte apoptosis.
Discussion
Accumulating evidence suggests that SCL is a key determinant
of bone mass in humans and blockage of SCL activity is currently
being explored as a novel treatment option for osteoporosis
[6,46,47]. Because of the high bone mass phenotype of individuals
carrying SOST mutations, as in the case of sclerosteosis patients, or
who lack SOST expression, in the case of Van Buchem’s disease, it
has been assumed that SCL is an inhibitor of bone formation.
However, it is possible that SCL also promotes bone catabolism,
an activity that is difficult to distinguish definitively from an anti-
anabolic activity in the current in vivo gene knockout and protein
neutralization models. In the current study, we observed that the
addition of exogenous rhSCL increased the level of expression of
RANKL mRNA and decreased that of OPG, in both cultures of
Figure 3. Effects of rhSCL on TRAP+ multinucleated cell
formation. The effect of rhSCL on osteoclastogenesis was tested in
co-cultures of MLO-Y4 cells with A) mouse splenocytes and B) human
PBMC. In both cases MLO-Y4 cells were seeded into type I collagen
coated culture wells and cultured for 72 h in the absence or presence of
rhSCL, as indicated, prior to the addition of either splenocytes or PBMC.
All cultures received rhM-CSF at 25 ng/ml. RhOPG was added to some
cultures at 100 ng/ml and rhRANKL (100 ng/ml) added to monocultures
of either splenocytes or PBMC to confirm the osteoclast-forming
potential of these populations (not shown). Media were replenished
every 3 days. Cultures were fixed and stained for TRAP at day 6. TRAP-
positive MNC, defined as cells with .3 nuclei, were counted from
quadruplicate wells. Asterisks denote significant differences to the no
SCL control (** p,0.01, *** p,0.001) and the effect of OPG relative to
the corresponding SCL-only treatment is indicated by W (p,0.001). C) In
the case of MLO-Y4/PBMC co-cultures and cells formed in PBMC
monocultures treated with rhRANKL, the relative size (in pixels) of
TRAP+ MNC formed (in each case .50 cells) was measured by Image J
analysis. Difference to the no SCL control is indicated by ** p,0.01;
{ indicates difference of rhRANKL control to rhSCL at 100 ng/ml (p,0.01).
Data shown are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0025900.g003
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human primary osteoblastic cells differentiated to an osteocyte-like
stage and in MLO-Y4 cells. Co-cultures of MLO-Y4 cells primed
with rhSCL and either mouse splenocytes or human PBMC,
showed that rhSCL promoted osteoclastogenesis. This was
associated with moderate increases in the number and size of
resulting TRAP+ multinucleated osteoclast-like cells. Importantly,
the osteoclasts formed in the presence of SCL had greatly
increased resorptive activity.
Our findings are consistent with a number of published
observations that indicate SCL may have catabolic actions in
bone. Li and co-workers demonstrated that mice lacking the Sost
gene display an osteopetrotic phenotype [48]. In a rat model,
neutralization of SCL in vivo resulted in protection from OVX-
induced bone loss associated with reduced osteoclast surface [18].
More recently, administration of a humanized neutralizing anti-
SCL antibody, AMG 785, to a healthy human cohort, rapidly and
dose-dependently decreased levels of the bone resorption marker,
serum CTx [6].
Consistent with our previous report, SCL in this study had
marked effects on pro-osteoclastogenic gene expression in cultures
of human primary osteoblasts that were first differentiated into an
osteocyte-like phenotype, compared with relatively minor effects
on immature cells [36]. The similarity of the response to that
observed in MLO-Y4 cells is also consistent with this effect of SCL
being on osteocytes. We previously showed that human osteocyte-
like cells were sensitive to the anti-anabolic effects of SCL at
concentrations as low as 1 ng/ml, concentrations that are higher
than but near to the levels reported in human serum of between
0.3 and 0.6 ng/ml [49,50,51]. This suggested that cells at the pre-
osteocyte and osteocyte stages are major physiological targets for
SCL [36]. In the present study, we found that SCL levels of
10 ng/ml or higher produced catabolic activity in these cells,
increasing RANKL and decreasing OPG expression. The negative
effect of SCL on OPG mRNA expression is consistent with
previous reports that SCL is an inhibitor of Wnt signalling and
that OPG is expressed in response to Wnt signalling [20,21]. The
regulation of OPG by Wnt signalling may be particularly pertinent
to our study as Wnt signalling in osteocytes has been shown to be
critical for the control of osteoclastogenesis in vivo: Kramer and
colleagues [52] demonstrated that conditional deletion of the gene
encoding b-catenin in osteocytes, under control of the osteocyte-
specific Dmp1 promoter, resulted in a severe low bone mass
phenotype characterised by elevated osteoclastic bone resorption,
which was thought to be driven by the observed reduced gene
expression of OPG. However, a pathway whereby SCL could
directly induce RANKL mRNA expression to a greater extent
than was seen on OPG expression mRNA, which appears to be
the case in our experimental systems, has not to our knowledge
been reported previously. Of note, histomorphometric analysis of
Sost-overexpressing (transgenic) mice revealed an osteopenic
phenotype but with no apparent effect on TRAP+ osteoclast
number [53,54]. This latter observation is consistent with our
findings using mouse splenocytes that SCL did not increase the
numbers of TRAP+ cells formed in co-cultures with MLO-Y4
cells, but specifically increased the resorbing activity of the
resulting cells. However, serum or urinary analysis of osteoclast
activity in Sost transgenic animals has not, to our knowledge, been
Figure 4. Effects of rhSCL on osteoclast resorptive activity. Co-
cultures of MLO-Y4 cells and A) mouse splenocytes and B) human PBMC
were established, in which MLO-Y4 cells were seeded onto bone-like
OsteologicTM slides and cultured for 72 h in the absence or presence of
rhSCL as indicated prior to the addition of either splenocytes or PBMC.
All cultures received rhM-CSF at 25 ng/ml and some cultures were
treated with rhOPG (100 ng/ml). Media were replenished every 3 days
for 14 days. Cells were removed and slides developed as described in
Materials and Methods and resorption. The entire surface areas of the
developed slides were imaged using an Olympus SZX10 dissecting
microscope at high resolution, depicted for the PBMC co-cultures below
the corresponding histograms in panel B) (red bars indicate 500 mm).
Total resorbed area was then quantified from quadruplicate wells using
ImageJ software. C) In the case of MLO-Y4/PBMC co-cultures, mean
resorption pit size was determined and expressed as fold-change from
the corresponding untreated co-culture. Differences to the ‘no SCL’
control in each panel are indicated by * p,0.05, ** p,0.01, *** p,0.001.
The effect of OPG relative to the corresponding SCL-only treatment is
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reported. It is also possible that transgenic chronic overexpression
of Sost triggers a negative feedback effect, which counters the effect
on osteoclast activity. This is supported by our observations in
human primary osteocyte-like cells that SCL only transiently up-
regulated the RANKL:OPG mRNA ratio cells, and by our
published observation that SCL down-regulates the expression at
least one of the known receptors for SCL, LRP4 [36]. It will be of
interest in future studies to examine acute versus chronic
administration of sclerostin in vivo. It also remains to be seen
which of the proposed receptors for SCL, including the LRPs 4, 5
and 6, are important for the responses observed in our study and
whether the effect is dependent on canonical or non-canonical
Wnt signalling, or indeed on BMP [8,12] and/or MAPK [17]
signalling.
Overall, our results indicate that in addition to an anti-anabolic
effect at lower doses, SCL at high doses may promote a catabolic
response by promoting osteoclast activity. Questions that arise
from our observations include, how do SCL-responding osteocytes
relate spatially to SCL-expressing cells, and, how in turn could this
affect osteoclastic bone resorption? In part answer to the latter
question, two very recent studies have established the critical
importance of osteocyte-expressed RANKL for bone remodelling
in the post-developmental skeleton in vivo, by targeted deletion of
RANKL expression in osteocytes, under control of the Dmp1
promoter; the loss of osteocyte-expressed RANKL results in a
severe osteopetrotic phenotype in these animals [55,56]. Since the
expression of SCL in vivo is by mature, mineral embedded
osteocytes [8,22,57,58], we propose that neighboring osteocytes,
those in closer proximity to endosteal surfaces than osteocytes
expressing high levels of SCL [22], may respond to a local,
catabolic stimulus-driven increase in SCL. The phenomenon we
observed in rhSCL-treated MLO-Y4/PBMC co-cultures of
increased activity per osteoclast is consistent with a pro-resorptive
response to SCL in vivo being spatially restricted to SCL-sensitive
osteocytes able to influence osteoclast precursors or osteoclasts
already in the process of resorbing bone. Our data suggest that this
influence would be at least partly via an increased local ratio of
RANKL:OPG in osteocytes.
Osteocyte cell death under certain circumstances is known to be
associated with the initiation of bone resorption [59,60]. Apoptotic
osteocytes have been shown to directly stimulate osteoclastogenesis
and bone resorption [61]. Prevention of bone fatigue-induced
osteocyte apoptosis has been show to block associated osteoclastic
resorption [62]. However, glucocorticoid-induced osteocyte apop-
tosis is associated with reduced osteoclastogenesis [63]. In the
current study, we observed no effect of sclerostin at the
concentrations used to stimulate osteoclastic activity on MLO-
Y4 cell viability over a 3 day treatment period, as assessed by
caspase-3 activation assays and examination of nuclear morphol-
ogy of treated cells. A previous study by Sutherland and colleagues
[64] reported that sclerostin could induce apoptosis of human
mesenchymal stem cells, but this was at concentrations of between
2–20 mg/ml, 20–200-fold higher than was used in this study and at
concentrations we would now consider as supra-physiological. In
addition, Kogianni and colleagues [61] reported that osteoclast
formation in response to osteocyte apoptotic bodies could not be
inhibited with exogenous OPG, whereas in our study the pro-
osteoclastic effects of SCL were strictly RANKL-dependent. Thus
our results strongly suggest that SCL promotes osteoclast
activation by viable osteocytes.
In summary, we have shown that SCL is capable of promoting
osteoclastogenesis and osteoclast resorptive activity by an effect on
osteocytes, in addition to its anti-anabolic effects. Our findings
help to explain the effects on the osteoclast/bone-resorption
compartment observed when SCL is neutralized in vivo.
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Figure 5. Effect of rhSCL on MLO-Y4 viability. A) Cells were
seeded into chamber slides and treated for 3 days A) untreated, or in
the presence of rhSCL at 50 ng/ml (B) or 100 ng/ml (C), or D) in the
presence of etoposide (50 mM). Cells were then fixed and their nuclear
morphology determined by staining with DAPI and visualization by
confocal microscopy. E) Cells were seeded into wells of a 6-well plate
and cultured for the times indicated with rhSCL (0–200 ng/ml) or in the
presence of etoposide (ETOP) at 50 mM. After the times indicated, cell
lysates were prepared and caspase 3 activity determined, as described
in Materials and Methods. Data are expressed as means of quadrupli-
cate wells 6 standard deviations.
doi:10.1371/journal.pone.0025900.g005
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